science
China syndrome? Phase II wins for Cue in CSU, stock melts down

Cue Biopharma Inc. is gearing up for a phase IIb/III study in chronic spontaneous urticaria (CSU, or hives), as well as a phase II in food allergy, after scoring in the mid-stage trial with CUE-221 in moderate to severe CSU.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Why this robot burns the tips off cotton plants with a Laser
Interesting Engineering

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research
Hoodline

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past
The Daily Galaxy

AI predicts pancreatic cancer years before diagnosis
Earth.com

Deployable Energy to test its nuclear battery at INL's DOME
Postregister